Product Category:

Anti-Rheumatoid Agents

Composition:

Diacerein Capsules IP (50mg)

Therapeutic Category:

Anthraquionone / symptomatic slow-acting drugs for OA (SYSADOAs)

Mechanism of Action:

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. Recent studies have shown it to have protective effects against subchondral bone remodeling. The primary mechanism of action of diacerein is the inhibition of interleukin-1β (IL-1β) system and related downstream signaling. It has also been shown to reduce the production of IL-1 converting enzyme and hence the activation of IL-1β. Downregulation of IL-1 levels has also been confirmed in the synovial fluid of patients with knee OA. (Pavelka et al., 2016) Pavelka, K., Bruyère, O., Cooper, C., Kanis, J. A., Leeb, B. F., Maheu, E., Martel-Pelletier, J., Monfort, J., Pelletier, J.-P., Rizzoli, R., & Reginster, J.-Y. (2016). Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs & Aging, 33(2), 75–85. https://doi.org/10.1007/s40266-016-0347-4

Indications:

For the treatment of osteoarthritis affecting the hip or knee

Dosage:

Usual dose: 50 mg twice daily (BD) Alternatively, 50 mg once daily with evening meal for 2-4 weeks. Dose may be increased to 100 mg daily in divided doses according to patient tolerability as directed by the physician. Treatment duration may vary according to patient response and expected clinical outcome.

Pack Size:

10*10s (Strips)